Results 61 to 70 of about 3,528 (147)
The BBIBP-CorV severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inactivated vaccine has been authorized for emergency use and widely distributed. We used single-cell transcriptome sequencing to characterize the dynamics of immune responses to
Jianhua Yin +47 more
doaj +1 more source
This study reports a patient developing TEN after the first dose of (BBIBP‐CorV). He developed numerous purpuric and dusky patches with flaccid bullae and areas of epidermal detachment covered more than 30% of the body area within 6 days. After treatment
Alireza hadizadeh, Safoura Shakoei
core +1 more source
Crude and adjusted effect of homologous vs. heterologous boosters on anti-Spike IgG and neutralizing Ab fourfold rise in primed recipients with ChAdOx1-S and BBIBP CorV.
Carmen Valenzuela Silva (17319206) +14 more
core +1 more source
Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines
The course of the COVID-19 pandemic has been critically altered by the availability of vaccines. To assess the risk of COVID-19 in the vaccinated, as compared to the unvaccinated population, as well as the comparative effectiveness of the BBIBP-CorV ...
Zoran Kokić +2 more
doaj +1 more source
Aging impairs vaccine efficacy through gut microbiota dysbiosis and mTOR hyperactivation, which together drive inflammaging and weaken immune memory. This review highlights the bidirectional microbiota–mTOR axis and proposes that combining mTOR inhibitors with microbiota modulation offers a promising strategy to enhance vaccine responses in older ...
Jiaxuan Li +5 more
wiley +1 more source
Estimates Vaccine effectiveness of inactivated vaccine BBIBP-CorV against COVID-19-associated severe or critical hospitalization according to vaccination status and by time since vaccination.
Redouane Abouqal (51120) +4 more
core +1 more source
Characterization of the Intestinal Microbiome in Healthy Adults over Sars-Cov-2 Vaccination
Background: In response to the outbreak of coronavirus disease 2019 (COVID-19) worldwide, inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are implemented.
Jie Jiao +7 more
doaj +1 more source
ABSTRACT Background and Aims Coronavirus disease‐2019 (COVID‐19) emerged in 2019 from Wuhan, China, leading to the accelerated development of vaccines, which have proven instrumental in controlling the spread of the virus. While vaccination ceased the increasing trend of the viral infection, rare adverse autoimmune events emerged as important ...
Mohammad Javad Yousefi‐Hashemabad +6 more
wiley +1 more source
Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old
Background and Objectives: In the current COVID-19 pandemic, children below the age of 12 could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community.
Manaf Al Qahtani +13 more
core +1 more source
BackgroundLong-term safety and efficacy of BBIBP-CorV vaccine especially in individuals with chronic diseases, like cancer, is under investigation. In the present prospective study, we aimed to evaluate severe acute respiratory syndrome-coronavirus-2 ...
Fahimeh Safarnezhad Tameshkel +11 more
doaj +1 more source

